PT1272177E - Método e formulação para o tratamento da resistência aos antihipertensos e condições associadas. - Google Patents
Método e formulação para o tratamento da resistência aos antihipertensos e condições associadas. Download PDFInfo
- Publication number
- PT1272177E PT1272177E PT00900110T PT00900110T PT1272177E PT 1272177 E PT1272177 E PT 1272177E PT 00900110 T PT00900110 T PT 00900110T PT 00900110 T PT00900110 T PT 00900110T PT 1272177 E PT1272177 E PT 1272177E
- Authority
- PT
- Portugal
- Prior art keywords
- melatonin
- patient
- formulation
- profile
- cortisol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims abstract description 12
- 238000009472 formulation Methods 0.000 title claims abstract description 10
- 239000002220 antihypertensive agent Substances 0.000 title description 7
- 229940030600 antihypertensive agent Drugs 0.000 title description 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 62
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 61
- 229960003987 melatonin Drugs 0.000 claims abstract description 61
- 239000003814 drug Substances 0.000 claims abstract description 14
- 238000013270 controlled release Methods 0.000 claims abstract description 11
- 230000000422 nocturnal effect Effects 0.000 claims abstract description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 42
- 229960000890 hydrocortisone Drugs 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 14
- 230000036772 blood pressure Effects 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000003607 modifier Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 108091006146 Channels Proteins 0.000 claims 1
- 102000004300 GABA-A Receptors Human genes 0.000 claims 1
- 108090000839 GABA-A Receptors Proteins 0.000 claims 1
- 108010064719 Oxyhemoglobins Proteins 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- -1 melatonin compound Chemical class 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010012374 Depressed mood Diseases 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000028327 secretion Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 102000003946 Prolactin Human genes 0.000 description 3
- 108010057464 Prolactin Proteins 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 3
- 229940097325 prolactin Drugs 0.000 description 3
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241001342895 Chorus Species 0.000 description 2
- 241000602850 Cinclidae Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
- 101800000989 Oxytocin Proteins 0.000 description 2
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 2
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- HAORKNGNJCEJBX-UHFFFAOYSA-N cyprodinil Chemical compound N=1C(C)=CC(C2CC2)=NC=1NC1=CC=CC=C1 HAORKNGNJCEJBX-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 229960001723 oxytocin Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 101150035983 str1 gene Proteins 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010003173 Arterial rupture Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010061174 Thyrotropin Chemical class 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- FROZIYRKKUFAOC-UHFFFAOYSA-N amobam Chemical compound N.N.SC(=S)NCCNC(S)=S FROZIYRKKUFAOC-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 238000000840 electrochemical analysis Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940042126 oral powder Drugs 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IL2000/000009 WO2001049286A1 (en) | 2000-01-05 | 2000-01-05 | Method and formulation for treating resistance to antihypertensives and related conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1272177E true PT1272177E (pt) | 2007-07-11 |
Family
ID=11042938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT00900110T PT1272177E (pt) | 2000-01-05 | 2000-01-05 | Método e formulação para o tratamento da resistência aos antihipertensos e condições associadas. |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US7332177B1 (enExample) |
| EP (1) | EP1272177B1 (enExample) |
| JP (1) | JP4996803B2 (enExample) |
| CN (1) | CN1414851A (enExample) |
| AT (1) | ATE359072T1 (enExample) |
| AU (1) | AU782266B2 (enExample) |
| BG (1) | BG65637B1 (enExample) |
| BR (1) | BR0016918A (enExample) |
| CA (1) | CA2396129C (enExample) |
| CY (2) | CY1108018T1 (enExample) |
| CZ (1) | CZ299931B6 (enExample) |
| DE (1) | DE60034373T2 (enExample) |
| DK (1) | DK1272177T3 (enExample) |
| EA (1) | EA004679B1 (enExample) |
| EE (1) | EE200200379A (enExample) |
| ES (1) | ES2284471T3 (enExample) |
| HK (1) | HK1052655A1 (enExample) |
| HU (1) | HU227002B1 (enExample) |
| IL (1) | IL150190A0 (enExample) |
| IS (1) | IS6439A (enExample) |
| MX (1) | MXPA02005783A (enExample) |
| NO (1) | NO322567B1 (enExample) |
| NZ (1) | NZ520078A (enExample) |
| PL (1) | PL201219B1 (enExample) |
| PT (1) | PT1272177E (enExample) |
| SI (1) | SI1272177T1 (enExample) |
| SK (1) | SK287508B6 (enExample) |
| TR (1) | TR200201724T2 (enExample) |
| TW (1) | TWI260983B (enExample) |
| UA (1) | UA77394C2 (enExample) |
| WO (1) | WO2001049286A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144900A (en) * | 2001-08-14 | 2013-12-31 | Neurim Pharma 1991 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
| US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
| IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Insomnia treatment |
| US20050020666A1 (en) * | 2003-07-25 | 2005-01-27 | Dabur Research Foundation | Cardioprotective agents |
| US20050137247A1 (en) * | 2003-12-22 | 2005-06-23 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of hypertension |
| JP3964417B2 (ja) | 2004-09-27 | 2007-08-22 | 国立大学法人金沢大学 | インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤 |
| KR101053780B1 (ko) * | 2008-02-29 | 2011-08-02 | 동아제약주식회사 | 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물 |
| EP2633376A4 (en) * | 2010-10-25 | 2015-02-18 | Uico Inc | CONTROL SYSTEM WITH A SOLID-RESISTANT TOUCH SENSOR FOR COMPLEX SURFACE GEOMETRY |
| WO2012103411A2 (en) | 2011-01-28 | 2012-08-02 | Zx Pharma, Llc | Controlled-release melatonin composition and related methods |
| US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
| EP3500163B1 (en) * | 2016-08-18 | 2025-02-19 | Koninklijke Philips N.V. | Blood-pressure management |
| US10849856B2 (en) | 2016-10-31 | 2020-12-01 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
| HUE070190T2 (hu) | 2016-10-31 | 2025-05-28 | Neurim Pharma 1991 | Melatonin minitabletták és eljárás azok elõállítására |
| WO2019038586A1 (en) | 2017-08-19 | 2019-02-28 | Ftf Pharma Private Limited | PHARMACEUTICAL COMPOSITION OF MELATONIN |
| ES2724933A1 (es) * | 2018-03-13 | 2019-09-17 | Ocupharm Diagnostics Sl | Terapia combinada con melatonina para la reducción de la presión intraocular |
| GB2617102A (en) * | 2022-03-29 | 2023-10-04 | John Hemming Trading Ltd | Sleep therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0518468T3 (da) * | 1991-05-09 | 2000-01-31 | Neurim Pharma 1991 | Melatoninholdige sammensætninger |
| WO1993007870A1 (en) * | 1991-10-18 | 1993-04-29 | Alza Corporation | Device for the transdermal administration of melatonin |
| US5646049A (en) | 1992-03-27 | 1997-07-08 | Abbott Laboratories | Scheduling operation of an automated analytical system |
| SG41955A1 (en) * | 1992-04-07 | 1997-08-15 | Neurim Pharma 1991 | Use of melatonin for the manufacture of a medicament for the treatment of benign prostatic hyperplasia |
| EP0664339A4 (en) | 1993-07-09 | 1999-04-28 | Wakunaga Seiyaku Kk | METHOD FOR DISCRIMINATION OF NUCLEIC ACIDS AND TEST KIT FOR THIS PURPOSE. |
| NZ298878A (en) | 1995-02-01 | 1999-05-28 | Neurim Pharma 1991 | Use of melatonin to treat addiction to benzodiazepines |
| US5648727A (en) | 1995-10-24 | 1997-07-15 | Dpc Cirrus Inc. | Capacitive level sensing pipette probe |
| US5700828A (en) | 1995-12-07 | 1997-12-23 | Life Resuscitation Technologies, Inc. | Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions |
| AU2583397A (en) * | 1996-04-10 | 1997-10-29 | Chronorx, Llc | Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions |
| RU2134108C1 (ru) | 1998-10-06 | 1999-08-10 | Заславская Рина Михайловна | Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии |
-
2000
- 2000-01-05 EA EA200200738A patent/EA004679B1/ru not_active IP Right Cessation
- 2000-01-05 SK SK973-2002A patent/SK287508B6/sk not_active IP Right Cessation
- 2000-01-05 DE DE60034373T patent/DE60034373T2/de not_active Expired - Lifetime
- 2000-01-05 HK HK03105037.1A patent/HK1052655A1/zh unknown
- 2000-01-05 PT PT00900110T patent/PT1272177E/pt unknown
- 2000-01-05 AT AT00900110T patent/ATE359072T1/de active
- 2000-01-05 WO PCT/IL2000/000009 patent/WO2001049286A1/en not_active Ceased
- 2000-01-05 PL PL356325A patent/PL201219B1/pl unknown
- 2000-01-05 MX MXPA02005783A patent/MXPA02005783A/es active IP Right Grant
- 2000-01-05 NZ NZ520078A patent/NZ520078A/en not_active IP Right Cessation
- 2000-01-05 ES ES00900110T patent/ES2284471T3/es not_active Expired - Lifetime
- 2000-01-05 IL IL15019000A patent/IL150190A0/xx unknown
- 2000-01-05 CZ CZ20022346A patent/CZ299931B6/cs not_active IP Right Cessation
- 2000-01-05 CA CA2396129A patent/CA2396129C/en not_active Expired - Lifetime
- 2000-01-05 CN CN00818153A patent/CN1414851A/zh active Pending
- 2000-01-05 BR BR0016918-8A patent/BR0016918A/pt not_active IP Right Cessation
- 2000-01-05 HU HU0204089A patent/HU227002B1/hu unknown
- 2000-01-05 EP EP00900110A patent/EP1272177B1/en not_active Expired - Lifetime
- 2000-01-05 TR TR2002/01724T patent/TR200201724T2/xx unknown
- 2000-01-05 SI SI200030958T patent/SI1272177T1/sl unknown
- 2000-01-05 AU AU18882/00A patent/AU782266B2/en not_active Expired
- 2000-01-05 EE EEP200200379A patent/EE200200379A/xx unknown
- 2000-01-05 US US10/169,467 patent/US7332177B1/en not_active Expired - Lifetime
- 2000-01-05 JP JP2001549654A patent/JP4996803B2/ja not_active Expired - Lifetime
- 2000-01-05 DK DK00900110T patent/DK1272177T3/da active
- 2000-05-01 UA UA2002076326A patent/UA77394C2/uk unknown
-
2001
- 2001-07-10 TW TW090116904A patent/TWI260983B/zh not_active IP Right Cessation
-
2002
- 2002-06-24 IS IS6439A patent/IS6439A/is unknown
- 2002-06-27 NO NO20023102A patent/NO322567B1/no not_active IP Right Cessation
- 2002-08-05 BG BG106978A patent/BG65637B1/bg unknown
-
2007
- 2007-07-10 CY CY20071100916T patent/CY1108018T1/el unknown
- 2007-12-04 US US11/950,039 patent/US8075914B2/en not_active Expired - Fee Related
- 2007-12-18 CY CY200700033C patent/CY2007033I1/el unknown
-
2011
- 2011-10-25 US US13/281,212 patent/US8728511B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1272177E (pt) | Método e formulação para o tratamento da resistência aos antihipertensos e condições associadas. | |
| TW576743B (en) | Extended release formulations of erythromycin derivatives | |
| EP1258245A2 (en) | Accelerated release composition containing bromocriptine | |
| KR960011772B1 (ko) | 개선된 디데옥시 퓨린 뉴클레오사이드 경구 투여 제제 | |
| RU2002113921A (ru) | Препаративные формы гидрокодона с контролируемым высвобождением | |
| GB2204490A (en) | Dehydroepiandrosterone | |
| JP2017132791A (ja) | 組み合わせ組成物 | |
| JPH05186332A (ja) | 少なくとも２種の異なる作用物質を備えた薬剤学的製剤の製造方法と使用 | |
| PT1069893E (pt) | Utilização de dexmedetomidina para sedação na uci | |
| US7015250B2 (en) | Methods and pharmaceutical preparations for normalizing blood pressure with (-)-hydroxycitric acid | |
| Bavitz | Emergency management of hypoglycemia and hyperglycemia | |
| CN103249304B (zh) | 用于治疗瘀伤的组合物和方法 | |
| JPS59199630A (ja) | 卵巣機能低下症治療剤 | |
| JP2004091473A (ja) | 色素沈着改善治療薬 | |
| WO2008057464A2 (en) | Compositions and methods for improving the bioavailability of liothyronine | |
| AU2016337564A1 (en) | Low dose oral dipyridamole compositions and uses thereof | |
| WO2007116287A1 (es) | Composición farmacéutica que comprende la combinación de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia. | |
| RU2132188C1 (ru) | Способ лечения гипофункции щитовидной железы | |
| US20250195455A1 (en) | Combination nasal and oral therapy for weight loss | |
| Lachnit et al. | Midazolam in the treatment of sleep disorders in geriatric patients. | |
| Maglinte et al. | The optimal dose of glucagon: what is enough. | |
| WO2019241495A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure | |
| US20040192781A1 (en) | Method of administration for metoclopramide and pharmaceutical formulation therefor | |
| RU2082397C1 (ru) | Способ лечения саркоидоза | |
| Levin et al. | Hepatitis associated with iproniazid (Marsilid®) Report of 3 cases |